利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.024 秒)

    Gene expression profiling of EGFR positive cancer
    1.
    发明申请
    Gene expression profiling of EGFR positive cancer 失效
    EGFR阳性癌基因表达谱

    公开(公告)号：US20050019785A1

    公开(公告)日：2005-01-27

    申请号：US10714195

    申请日：2003-11-14

    申请人： Joffre Baker ,  Maureen Cronin ,  Steve Shak ,  Jose Baselga

    发明人： Joffre Baker ,  Maureen Cronin ,  Steve Shak ,  Jose Baselga

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/16

    摘要： The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.

    摘要翻译： 本发明涉及与EGFR阳性癌症相关的预后标志物。 特别地，本发明涉及基于在石蜡包埋的EGFR表达癌症的固定组织样品中的基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂的治疗反应良好 。

    Antibodies Against HER2 Truncated Variant CTF-611
    4.
    发明申请
    Antibodies Against HER2 Truncated Variant CTF-611 有权
    针对HER2截断变异体CTF-611的抗体

    公开(公告)号：US20110135653A1

    公开(公告)日：2011-06-09

    申请号：US12961004

    申请日：2010-12-06

    申请人： Joaquin Arribas Lopez ,  Kim Pedersen ,  Pier-Davide Angellini ,  Josep Lluis Parra Palau ,  Jose Baselga Torres

    发明人： Joaquin Arribas Lopez ,  Kim Pedersen ,  Pier-Davide Angellini ,  Josep Lluis Parra Palau ,  Jose Baselga Torres

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N5/16 ,  C12P21/00 ,  G01N33/53 ,  A61P35/00

    CPC分类号： C07K16/32 ,  A61K2039/505 ,  C07K2317/34

    摘要： The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor.The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6).The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

    摘要翻译： 本发明涉及一种诊断和治疗表达HER2受体的癌症的方法。 本发明提供识别CTF-611截断的HER2受体的表位的抗体或其片段，所述表位由SEQ ID NO：2所包含的序列定义，并且能够区分CTF-611和CTF-616 （由SEQ ID NO：7表示），优选另外能够区分CTF-611和CTF-613（由SEQ ID NO：6表示）。 本发明还提供使用所公开抗体的癌症诊断方法，其包括检测患者样品中由氨基酸序列SEQ ID NO：1组成的HER2受体截短形式的存在。

    Antibodies against HER2 truncated variant CTF-611
    6.
    发明授权
    Antibodies against HER2 truncated variant CTF-611 有权
    针对HER2截短型CTF-611的抗体

    公开(公告)号：US08741586B2

    公开(公告)日：2014-06-03

    申请号：US12961004

    申请日：2010-12-06

    申请人： Joaquin Arribas Lopez ,  Kim Pedersen ,  Pier-Davide Angellini ,  Josep Lluis Parra Palau ,  Jose Baselga Torres

    发明人： Joaquin Arribas Lopez ,  Kim Pedersen ,  Pier-Davide Angellini ,  Josep Lluis Parra Palau ,  Jose Baselga Torres

    IPC分类号： C12P21/08 ,  C07K16/30 ,  C07K16/28 ,  G01N33/574 ,  G01N33/573 ,  G01N33/567 ,  G01N33/50

    CPC分类号： C07K16/32 ,  A61K2039/505 ,  C07K2317/34

    摘要： The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor.The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6).The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

    摘要翻译： 本发明涉及一种诊断和治疗表达HER2受体的癌症的方法。 本发明提供识别CTF-611截断的HER2受体的表位的抗体或其片段，所述表位由SEQ ID NO：2所包含的序列定义，并且能够区分CTF-611和CTF-616 （由SEQ ID NO：7表示），优选另外能够区分CTF-611和CTF-613（由SEQ ID NO：6表示）。 本发明还提供使用所公开抗体的癌症诊断方法，其包括检测患者样品中由氨基酸序列SEQ ID NO：1组成的HER2受体截短形式的存在。